A public review into the three-person in vitro fertilisation (IVF) technique has been broadly supportive, the Department of Health said, citing the nearly 2,000 responses received during public consultations.
But a number of technical and scientific details need to be finalised before the plans go before Parliament, the BBC reported today.
The move would be restricted to mitochondrial disease, affecting one in 6,500 UK babies born each year. This may lead to muscle weakness, blindness, and heart failure.
An expert scientific panel has already suggested there is no evidence the procedure is unsafe but has asked for a number of further investigations to be carried out.
The government expects other details to be finalised in the next few months before the plans are legalised.
Ministers agreed that the regulatory body the Human Fertilisation Embryology Authority would consider each application from parents on a case-by-case basis.
And any children born using the procedure would not be able to find out the identity of the mitochondrial donor.
As mitochondria are passed down from mother to child, using an extra egg from a donor woman could give the child healthy mitochondria.
However, it would also result in babies having DNA from two parents and a tiny amount (1 per cent) from the donor as mitochondria have their own DNA.
Opponents say it is unethical and could set the UK on a "slippery slope" to designer babies.
Dr Jeremy Farrar, director of the Wellcome Trust, said: "There is broad public support for making mitochondrial replacement therapy available to patients.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
